Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David McKellar

Pain Medicine Hattiesburg, MS Medical Doctor

NPI 1700947579 CMS profile 168339

106 Asbury Cir, Hattiesburg, MS 39402

Open in the dashboard

General payments

$2,369

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David McKellar of Hattiesburg, MS is reported in the CMS Open Payments database as having received $2,369 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $192 9
2024 General $47 3
2023 General $18 1
2022 General $117 2
2021 General $27 2
2020 General $108 6
2019 General $1,859 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David McKellar
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to David McKellar were reported at $192. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year David McKellar Pain Medicine median Middle half National median
2019 $1,859 $498 $126–$1,682 $163
2020 $108 $284 $80–$910 $114
2021 $27 $399 $112–$1,219 $132
2022 $117 $455 $137–$1,484 $149
2023 $18 $484 $128–$1,495 $160
2024 $47 $498 $131–$1,540 $164
2025 $192 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,747 16 payments
  2. Boston Scientific Corporation $229 11 payments
  3. BIOTRONIK NRO, Inc. $92 3 payments
  4. Abbott Laboratories $76 3 payments
  5. Valinor Pharma, LLC $65 4 payments
  6. Medtronic USA, Inc. $56 3 payments
  7. Forte Bio-Pharma LLC $33 2 payments
  8. Medtronic, Inc. $19 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $18 1 payment
  10. Shionogi Inc $18 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,409 3 payments
  2. Food and Beverage $960 43 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $1,747 16 payments
  2. General - Therapies $103 2 payments
  3. Prospera $92 3 payments
  4. MOVANTIK $65 4 payments
  5. SPECTRA WAVEWRITER $64 5 payments
  6. INTELLIS $56 3 payments
  7. Proclaim Family of SCS IPGs $48 2 payments
  8. PROLATE Pain $33 2 payments
  9. PROLATE Pain $33 2 payments
  10. NALOCET $33 2 payments
  11. Other $193 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

140

Median for Interventional Pain Management: 1,220

Drug cost

$3,307

Median for Interventional Pain Management: $39,344

Branded share of claims

85%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Morphine Sulfate Er Morphine Sulfate Brand 22 $1,132
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 40 $991
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $852
Gabapentin Generic 21 $333

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$109,079

Medicare's payments for the services billed

Medicare patients

344

Average age 74

Services billed

1,889

203 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Depression 35%
Diabetes 33%
Chronic kidney disease 19%
COPD 16%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOVANTIK
  • Valinor Pharma, LLC $15
$15 — —
PROLATE
  • Forte Bio-Pharma LLC $13
$13 — —
NALOCET
  • Forte Bio-Pharma LLC $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record